30 results
8-K
EX-99.1
QNCX
Quince Therapeutics Inc
24 Jul 23
Entry into a Material Definitive Agreement
7:16am
, slow release of dexamethasone over several weeks without long-term toxicity typically associated with chronic steroid administration Plan to enroll … up to 10+ years of chronic steroid administration without typical safety issues 21 4 4
EryDel acquisition transaction details Overview Stock
8-K
EX-99.2
QNCX
Quince Therapeutics Inc
24 Jul 23
Entry into a Material Definitive Agreement
7:16am
) technology
designed for slow release of steroids over several weeks without long-term toxicity
typically associated with chronic administration …
Potential for rapid expansion of EryDex to other rare and debilitating disease indications
where chronic steroid treatment is or could become the standard
424B5
38lydj a26yj1x7aqjuc
19 May 22
Prospectus supplement for primary offering
4:44pm
POS AM
jnnz17vgmvho7d8xjzo
4 Mar 22
Prospectus update (post-effective amendment)
4:04pm
POSASR
jprfetlx45qtcjze
7 Feb 22
Automatic shelf registration (post-effective amendment)
5:01pm